Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Whissell

Psychiatry Atlanta, GA Medical Doctor

NPI 1881603553 CMS profile 85399

The Center For Health And Rehabilitation, 265 Boulevard Ne, Atlanta, GA 30312

Open in the dashboard

General payments

$5,754

298 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Whissell of Atlanta, GA is reported in the CMS Open Payments database as having received $5,754 across 298 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,047 59
2024 General $936 43
2023 General $1,202 58
2022 General $952 47
2021 General $668 31
2020 General $449 24
2019 General $501 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Whissell
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to William Whissell were reported at $1,047. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year William Whissell Psychiatry median Middle half National median
2019 $501 $184 $59–$605 $163
2020 $449 $119 $36–$372 $114
2021 $668 $143 $43–$576 $132
2022 $952 $153 $50–$590 $149
2023 $1,202 $170 $56–$651 $160
2024 $936 $179 $57–$673 $164
2025 $1,047 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teva Pharmaceuticals USA, Inc. $1,180 76 payments
  2. Janssen Pharmaceuticals, Inc $963 54 payments
  3. Alkermes, Inc. $755 38 payments
  4. Otsuka America Pharmaceutical, Inc. $669 35 payments
  5. Indivior Inc. $463 17 payments
  6. Neurocrine Biosciences, Inc. $459 18 payments
  7. AbbVie, Inc. $261 14 payments
  8. Sunovion Pharmaceuticals Inc. $233 11 payments
  9. Lundbeck LLC $215 10 payments
  10. ITI, Inc. $164 8 payments
  11. Other $393 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,634 296 payments
  2. Education $120 2 payments
Products named General payments · program years 2019–2025
  1. INVEGA SUSTENNA $901 50 payments
  2. ABILIFY MAINTENA $738 37 payments
  3. ARISTADA Cns $715 36 payments
  4. ARISTADA Cns $715 36 payments
  5. ARISTADA Cns $611 31 payments
  6. ARISTADA Cns $611 31 payments
  7. INVEGA TRINZA $526 29 payments
  8. AUSTEDO $493 33 payments
  9. SPRAVATO $471 27 payments
  10. PERSERIS $463 17 payments
  11. Other $3,702 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 47 drugs

Part D claims

3,380

Median for Psychiatry & Neurology: 100

Drug cost

$1,742,266

Median for Psychiatry & Neurology: $2,986

Branded share of claims

24.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Trinza Paliperidone Palmitate Brand 109 $832,903
Invega Sustenna Paliperidone Palmitate Brand 194 $582,105
Ingrezza Valbenazine Tosylate Brand 11 $92,722
Abilify Maintena Aripiprazole Brand 18 $51,830
Vraylar Cariprazine Hcl Brand 24 $35,075
Lurasidone Hcl Generic 72 $28,487
Lybalvi Olanzapine/Samidorphan Malate Brand 13 $23,120
Paliperidone Er Paliperidone Brand 60 $18,597
Aripiprazole Generic 163 $13,179
Ziprasidone Hcl Generic 122 $10,506

The 10 drugs with the highest cost, of 47 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $125
$125 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $74
  • Lundbeck LLC $28
$102 18 —
INGREZZA
  • Neurocrine Biosciences, Inc. $99
$99 11 —
PERSERIS
  • Indivior Inc. $99
$99 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $78
$78 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

298 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record